Search clinical trials for: AS02A

Total 17 results

GlaxoSmithKline

Completed

Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants

Asthma

Netherlands
National Institute of Allergy and Infectious Diseases...

Completed

An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV

HIV Infections

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.

Plasmodium Falciparum

Kenya
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); Walter... and other collaborators

Completed

Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine

Malaria, Falciparum

Kenya
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.

Malaria

Mozambique
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR); The PATH Malaria...

Completed

Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America

Malaria | Plasmodium Falciparum Malaria

United States
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline and other collaborators

Completed

Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali

Plasmodium Falciparum Malaria

Mali
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); Walter... and other collaborators

Completed

Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children

Plasmodium Falciparum Malaria

Kenya
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline and other collaborators

Completed

Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali

Malaria

Mali
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline and other collaborators

Completed

FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali

Malaria | Plasmodium Falciparum Malaria

Mali
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults

Tuberculosis (TB)

Switzerland
GlaxoSmithKline

Completed

Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine

Malaria

Mozambique
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.

Malaria

Mozambique
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); The...

Completed

A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults

Malaria

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria

Malaria

United States
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Completed

Phase I Pediatric FMP2.1/AS02A Trial in Mali

Plasmodium Falciparum Malaria

Mali
Marcus Altfeld, M.D., Ph.D.
GlaxoSmithKline

Completed

Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)

HIV Infections

United States

Search clinical trials for: AS02A

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations